XML 57 R36.htm IDEA: XBRL DOCUMENT
v3.25.1

SEGMENTS (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
SEGMENTS [Abstract] |
Summarized Financial Information Concerning Reportable Segments | Summarized financial information concerning reportable segments is shown in the following tables:
Year Ended December 31, 2024 |
(in thousands) |  | ADMA BioManufacturing |  |  | Plasma Collection Centers |  |  | Total |
Revenues |  | $ | 415,806 |  |  | $ | 10,505 |  |  | $ | 426,311 |
Cost of product revenue |  |  | 195,605 |  |  |  | 11,296 |  |  |  | 206,901 |
Research and development |  |  | 1,813 |  |  |  | - |  |  |  | 1,813 |
Plasma center operating expenses |  |  | - |  |  |  | 4,245 |  |  |  | 4,245 |
Selling, marketing and distribution |  |  | 18,683 |  |  |  | - |  |  |  | 18,683 |
Depreciation and amortization expense |  |  | 4,827 |  |  |  | 3,218 |  |  |  | 8,045 |
General and administrative expense |  |  | 26,001 |  |  |  | - |  |  |  | 26,001 |
Other expense, net |  |  | (178 | ) |  |  | (5 | ) |  |  | (183 | )
Income (loss) before taxes |  |  | 173,138 |  |  |  | (5,041 | ) |  |  | 168,097 |
Expenditures for additions to long-lived assets |  |  | 8,352 |  |  |  | 223 |  |  |  | 8,575 |
Total assets |  |  | 289,297 |  |  |  | 30,477 |  |  |  | 319,774 |
Reconciliation of revenues: |  |  |  |  |  |  |  |  |  |  |  |
Segment revenue |  |  |  |  |  |  |  |  |  | $ | 426,311 |
License revenue (see Note 2 - Revenue Recognition) |  |  |  |  |  |  |  |  |  |  | 143 |
Consolidated revenues |  |  |  |  |  |  |  |  |  | $ | 426,454 |
Reconciliation of selling, general and administrative expense: |  |  |  |  |  |  |  |  |  |  |  |
Segment selling, marketing and distribution expense |  |  |  |  |  |  |  |  |  | $ | 18,683 |
Segment general and administrative expense |  |  |  |  |  |  |  |  |  |  | 26,001 |
Corporate general and administrative expense (a) |  |  |  |  |  |  |  |  |  |  | 29,440 |
Consolidated selling, general and administrative expense |  |  |  |  |  |  |  |  |  | $ | 74,124 |
Reconciliation of income (loss) before taxes: |  |  |  |  |  |  |  |  |  |  |  |
Segment income before taxes |  |  |  |  |  |  |  |  |  | $ | 168,097 |
License revenue |  |  |  |  |  |  |  |  |  |  | 143 |
Unallocated interest expense, primarily related to interest on senior debt (see Note 7) |  |  |  |  |  |  |  |  |  |  | (13,930 | )
Loss on extinguishment of debt (see Note 7) |  |  |  |  |  |  |  |  |  |  | (1,243 | )
Unallocated interest income |  |  |  |  |  |  |  |  |  |  | 2,087 |
Corporate general and administrative expense (a) |  |  |  |  |  |  |  |  |  |  | (29,440 | )
Consolidated income before taxes |  |  |  |  |  |  |  |  |  | $ | 125,714 |
Reconciliation of total assets: |  |  |  |  |  |  |  |  |  |  |  |
Total segment assets |  |  |  |  |  |  |  |  |  | $ | 319,774 |
Corporate (b) |  |  |  |  |  |  |  |  |  |  | 168,904 |
Consolidated total assets |  |  |  |  |  |  |  |  |  | $ | 488,678 |
(a) - | Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company’s operating segments.
(b) - | Primarily consists of cash and deferred tax assets.
Year Ended December 31, 2023 |
(in thousands) |  | ADMA BioManufacturing |  |  | Plasma Collection Centers |  |  | Total |
Revenues |  | $ | 249,738 |  |  | $ | 8,334 |  |  | $ | 258,072 |
Cost of product revenue |  |  | 161,157 |  |  |  | 8,116 |  |  |  | 169,273 |
Research and development |  |  | 3,300 |  |  |  | - |  |  |  | 3,300 |
Plasma center operating expenses |  |  | - |  |  |  | 4,266 |  |  |  | 4,266 |
Selling, marketing and distribution |  |  | 18,407 |  |  |  | - |  |  |  | 18,407 |
Depreciation and amortization expense |  |  | 5,156 |  |  |  | 3,176 |  |  |  | 8,332 |
General and administrative expense |  |  | 18,625 |  |  |  | - |  |  |  | 18,625 |
Income (loss) before taxes |  |  | 47,267 |  |  |  | (4,049 | ) |  |  | 43,218 |
Expenditures for additions to long-lived assets |  |  | 2,952 |  |  |  | 1,819 |  |  |  | 4,771 |
Total assets |  |  | 246,719 |  |  |  | 34,733 |  |  |  | 281,452 |
Reconciliation of revenues: |  |  |  |  |  |  |  |  |  |  |  |
Segment revenue |  |  |  |  |  |  |  |  |  | $ | 258,072 |
License revenue (see Note 2 - Revenue Recognition) |  |  |  |  |  |  |  |  |  |  | 143 |
Consolidated revenues |  |  |  |  |  |  |  |  |  | $ | 258,215 |
Reconciliation of selling, general and administrative expense: |  |  |  |  |  |  |  |  |  |  |  |
Segment selling, marketing and distribution expense |  |  |  |  |  |  |  |  |  | $ | 18,407 |
Segment general and administrative expense |  |  |  |  |  |  |  |  |  |  | 18,625 |
Corporate general and administrative expense (a) |  |  |  |  |  |  |  |  |  |  | 21,988 |
Consolidated selling, general and administrative expense |  |  |  |  |  |  |  |  |  | $ | 59,020 |
Reconciliation of income (loss) before taxes: |  |  |  |  |  |  |  |  |  |  |  |
Segment income before taxes |  |  |  |  |  |  |  |  |  | $ | 43,218 |
License revenue |  |  |  |  |  |  |  |  |  |  | 143 |
Unallocated interest expense, primaril related to interest on senior debt (see Note 7) |  |  |  |  |  |  |  |  |  |  | (25,027 | )
Loss on extinguishment of debt (see Note 7) |  |  |  |  |  |  |  |  |  |  | (26,174 | )
Unallocated interest income |  |  |  |  |  |  |  |  |  |  | 1,589 |
Corporate general and administrative expense (a) |  |  |  |  |  |  |  |  |  |  | (21,988 | )
Consolidated income before taxes |  |  |  |  |  |  |  |  |  | $ | (28,239 | )
Reconciliation of total assets: |  |  |  |  |  |  |  |  |  |  |  |
Total segment assets |  |  |  |  |  |  |  |  |  | $ | 281,452 |
Corporate (b) |  |  |  |  |  |  |  |  |  |  | 47,730 |
Consolidated total assets |  |  |  |  |  |  |  |  |  | $ | 329,182 |
(a) - | Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company’s operating segments.
(b) - | Primarily consists of cash.
Year Ended December 31, 2022 |
(in thousands) |  | ADMA BioManufacturing |  |  | Plasma Collection Centers |  |  | Total |
Revenues |  | $ | 144,070 |  |  | $ | 9,867 |  |  | $ | 153,937 |
Cost of product revenue |  |  | 108,882 |  |  |  | 9,933 |  |  |  | 118,815 |
Research and development |  |  | 3,614 |  |  |  | - |  |  |  | 3,614 |
Plasma center operating expenses |  |  | - |  |  |  | 17,843 |  |  |  | 17,843 |
Selling, marketing and distribution |  |  | 13,667 |  |  |  | - |  |  |  | 13,667 |
Depreciation and amortization expense |  |  | 4,709 |  |  |  | 2,404 |  |  |  | 7,113 |
General and administrative expense |  |  | 16,312 |  |  |  | - |  |  |  | 16,312 |
Income (loss) before taxes |  |  | 374 |  |  |  | (17,911 | ) |  |  | (17,537 | )
Expenditures for additions to long-lived assets |  |  | 5,247 |  |  |  | 8,664 |  |  |  | 13,911 |
Total assets |  |  | 238,159 |  |  |  | 37,071 |  |  |  | 275,230 |
Reconciliation of revenues: |  |  |  |  |  |  |  |  |  |  |  |
Segment revenue |  |  |  |  |  |  |  |  |  | $ | 153,937 |
License revenue (see Note 2 - Revenue Recognition) |  |  |  |  |  |  |  |  |  |  | 143 |
Consolidated revenues |  |  |  |  |  |  |  |  |  | $ | 154,080 |
Reconciliation of selling, general and administrative expense: |  |  |  |  |  |  |  |  |  |  |  |
Segment selling, marketing and distribution expense |  |  |  |  |  |  |  |  |  | $ | 13,667 |
Segment general and administrative expense |  |  |  |  |  |  |  |  |  |  | 16,312 |
Corporate general and administrative expense (a) |  |  |  |  |  |  |  |  |  |  | 22,479 |
Consolidated selling, general and administrative expense |  |  |  |  |  |  |  |  |  | $ | 52,458 |
Reconciliation of income (loss) before taxes: |  |  |  |  |  |  |  |  |  |  |  |
Segment income before taxes |  |  |  |  |  |  |  |  |  | $ | (17,537 | )
License revenue |  |  |  |  |  |  |  |  |  |  | 143 |
Unallocated interest expense, primaril related to interest on senior debt (see Note 7) |  |  |  |  |  |  |  |  |  |  | (19,276 | )
Loss on extinguishment of debt (see Note 7) |  |  |  |  |  |  |  |  |  |  | (6,670 | )
Other expense |  |  |  |  |  |  |  |  |  |  | (85 | )
Corporate general and administrative expense (a) |  |  |  |  |  |  |  |  |  |  | (22,479 | )
Consolidated income before taxes |  |  |  |  |  |  |  |  |  | $ | (65,904 | )
Reconciliation of total assets: |  |  |  |  |  |  |  |  |  |  |  |
Total segment assets |  |  |  |  |  |  |  |  |  | $ | 275,230 |
Corporate (b) |  |  |  |  |  |  |  |  |  |  | 73,231 |
Consolidated total assets |  |  |  |  |  |  |  |  |  | $ | 348,461 |
(a) - | Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company’s operating segments.
(b) - | Primarily consists of cash.
Net Revenues According to Geographic Area | Net revenues according to geographic area, based on the location of where the product is shipped, are as follows:
|  | Year Ended December 31, 2024 |
|  | ADMA BioManufacturing |  |  | Plasma Centers |  |  | Total Segment Revenue |  |  | License Revenue |  |  | Consolidated Revenue |
United States |  | $ | 400,336 |  |  | $ | 9,669 |  |  | $ | 410,005 |  |  | $ | 143 |  |  | $ | 410,148 |
International |  |  | 15,470 |  |  |  | 836 |  |  |  | 16,306 |  |  |  | - |  |  |  | 16,306 |
Total revenues |  | $ | 415,806 |  |  | $ | 10,505 |  |  | $ | 426,311 |  |  | $ | 143 |  |  | $ | 426,454 |
|  | Year Ended December 31, 2023 |
|  | ADMA BioManufacturing |  |  | Plasma Centers |  |  | Total Segment Revenue |  |  | License Revenue |  |  | Consolidated Revenue |
United States |  | $ | 237,454 |  |  | $ | 7,284 |  |  | $ | 244,738 |  |  | $ | 143 |  |  | $ | 244,881 |
International |  |  | 12,284 |  |  |  | 1,050 |  |  |  | 13,334 |  |  |  | - |  |  |  | 13,334 |
Total revenues |  | $ | 249,738 |  |  | $ | 8,334 |  |  | $ | 258,072 |  |  | $ | 143 |  |  | $ | 258,215 |
|  | Year Ended December 31, 2022 |
|  | ADMA BioManufacturing |  |  | Plasma Centers |  |  | Total Segment Revenue |  |  | License Revenue |  |  | Consolidated Revenue |
United States |  | $ | 136,827 |  |  | $ | 9,457 |  |  | $ | 146,284 |  |  | $ | 143 |  |  | $ | 146,427 |
International |  |  | 7,243 |  |  |  | 410 |  |  |  | 7,653 |  |  |  | - |  |  |  | 7,653 |
Total revenues |  | $ | 144,070 |  |  | $ | 9,867 |  |  | $ | 153,937 |  |  | $ | 143 |  |  | $ | 154,080 |

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration